Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage

Show simple item record

dc.contributor.author Scheepers, Cathrine
dc.contributor.author Everatt, Josie
dc.contributor.author Amoako, Daniel G.
dc.contributor.author Tegally, Houriiyah
dc.contributor.author Wibmer, Constantinos Kurt
dc.contributor.author Mnguni, Anele
dc.contributor.author Ismail, Arshad
dc.contributor.author Mahlangu, Boitshoko
dc.contributor.author Lambson, Bronwen E.
dc.contributor.author Martin, Darren P.
dc.contributor.author Wilkinson, Eduan
dc.contributor.author San, James Emmanuel
dc.contributor.author Giandhari, Jennifer
dc.contributor.author Manamela, Nelia
dc.contributor.author Ntuli, Noxolo
dc.contributor.author Kgagudi, Prudence
dc.contributor.author Cele, Sandile
dc.contributor.author Richardson, Simone I.
dc.contributor.author Pillay, Sureshnee
dc.contributor.author Mohale, Thabo
dc.contributor.author Ramphal, Upasana
dc.contributor.author Naidoo, Yeshnee
dc.contributor.author Khumalo, Zamantungwa Thobeka Happiness
dc.contributor.author Kwatra, Gaurav
dc.contributor.author Gray, Glenda
dc.contributor.author Bekker, Linda‑Gail
dc.contributor.author Madhi, Shabir A.
dc.contributor.author Baillie, Vicky
dc.contributor.author Van Voorhis, Wesley C.
dc.contributor.author Treurnicht, Florette K.
dc.contributor.author Venter, Marietjie
dc.contributor.author Mlisana, Koleka
dc.contributor.author Wolter, Nicole
dc.contributor.author Sigal, Alex
dc.contributor.author Williamson, Carolyn
dc.contributor.author Hsiao, Nei-yuan
dc.contributor.author Msomi, Nokukhanya
dc.contributor.author Maponga, Tongai
dc.contributor.author Preiser, Wolfgang
dc.contributor.author Makatini, Zinhle
dc.contributor.author Lessells, Richard
dc.contributor.author Moore, Penny L.
dc.contributor.author De Oliveira, Tulio
dc.contributor.author Von Gottberg, Anne
dc.contributor.author Bhiman, Jinal N.
dc.date.accessioned 2023-11-20T11:53:17Z
dc.date.available 2023-11-20T11:53:17Z
dc.date.issued 2022-04-08
dc.description CODE AVAILABILITY : The R and python scripts used to generate figures (excluding bar charts) in this paper are available at https://github.com/NICD-CRDM/C.1.2_scripts. The Nextstrain build profile, other scripts required to run the custom pipeline, and GISAID accession identifiers for all sequences in the final tree are available at https://github.com/NICD-CRDM/ C.1.2_scripts/tree/main/Nextstrain_files. The MATLAB scripts used for microscopy are available at https://github.com/NICD-CRDM/C.1.2_scripts/tree/main/microscopy. This code is also available in Supplementary Software 1. en_US
dc.description DATA AVAILABILITY : All of the global SARS-CoV-2 genomes generated and presented in this article are publicly accessible through the GISAID9 platform (https://www.gisaid.org/), along with all other SARS-CoV-2 genomes generated by the NGS-SA. The GISAID accession identifiers of the C.1.2 sequences analyzed in this study are provided as part of Supplementary Tables 1 and 2, which also contain the metadata for the sequences. The Nextstrain build of C.1.2 and global sequences is available at https://nextstrain.org/ groups/ngs-sa/COVID19-C.1.2-2022-01-05. The GISAID accession identifiers for the full set of sequences used in this build can be accessed at https://github.com/NICD-CRDM/ C.1.2_scripts/tree/main/Nextstrain_files. The GISAID accession identifiers for the sequences used in Supp. Fig. 2a and temporal analysis can be accessed at https:// github.com/NICD-CRDM/C.1.2_scripts in the files violin_plot_IDs.xlsx and C.1.2_global_tempest.xlsx respectively. The shapefile used for South African maps in Supplementary Fig. 1 was downloaded from https://gadm.org/ (licensed for use in academic publications, see https://gadm.org/license.html) and visualised in R with ggplot2. The global map in Supplementary Fig. 1 was obtained from the rnaturalearth package (public domain, see https://docs.ropensci.org/rnaturalearth/articles/ rnaturalearth.html) and visualised with ggplot2. The data was based on sequences available on GISAID at the time. en_US
dc.description.abstract Global genomic surveillance of SARS-CoV-2 has identified variants associated with increased transmissibility, neutralization resistance and disease severity. Here we report the emergence of the PANGO lineage C.1.2, detected at low prevalence in South Africa and eleven other countries. The initial C.1.2 detection is associated with a high substitution rate, and includes changes within the spike protein that have been associated with increased transmissibility or reduced neutralization sensitivity in SARS-CoV-2 variants of concern or variants of interest. Like Beta and Delta, C.1.2 shows significantly reduced neutralization sensitivity to plasma from vaccinees and individuals infected with the ancestral D614G virus. In contrast, convalescent donors infected with either Beta or Delta show high plasma neutralization against C.1.2. These functional data suggest that vaccine efficacy against C.1.2 will be equivalent to Beta and Delta, and that prior infection with either Beta or Delta will likely offer protection against C.1.2. en_US
dc.description.department Medical Virology en_US
dc.description.department Veterinary Tropical Diseases en_US
dc.description.librarian am2023 en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.description.sponsorship The Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation. Sequencing activities for the different sequencing hubs were provided by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response, a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention; the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation; the UK Foreign, Commonwealth and Development Office and Wellcome; the South African Medical Research Council; the UK Department of Health and Social Care and managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project; German Federal Ministry of Education and Research for the African Network for Improved Diagnostics, Epidemiology and Management of common infectious Agents (ANDEMIA). This study was supported by the Bill and Melinda Gates award, National Institutes of Health, South African Medical Research Council and National Institutes of Health. Hyrax Biosciences’ Exatype platform was supported by the South African Medical Research Council with funds received from the Department of Science and Innovation. en_US
dc.description.uri http://www.nature.com/naturecommunications en_US
dc.identifier.citation Scheepers, C., Everatt, J., Amoako, D.G. et al. 2022, 'Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage', Nature Communications, vol. 13, no. 1976, pp. 1-9. DOI : 10.1038/s41467-022-29579-9. en_US
dc.identifier.issn 2041-1723 (online)
dc.identifier.other 10.1038/s41467-022-29579-9
dc.identifier.uri http://hdl.handle.net/2263/93366
dc.language.iso en en_US
dc.publisher Nature Research en_US
dc.rights © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License. en_US
dc.subject PANGO lineage C.1.2 en_US
dc.subject Variants en_US
dc.subject Beta or Delta en_US
dc.subject Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) en_US
dc.subject SDG-03: Good health and well-being en_US
dc.title Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record